Categories AlphaGraphs, Earnings
AngioDynamics misses Q3 revenue expectation; reports double digit earnings growth
Medical device manufacturer AngioDynamics’ (ANGO) third quarter 2018 revenue fell short of consensus estimate. The company’s revenue dropped 2.1% year-over-year, while the US tax reform lifted the reported earnings and per share figures, which more than tripled for the quarter. The revenue miss was mainly due to the declines in the Venous Insufficiency business and a negative year-over-year comparison related to the Radiofrequency Ablation (RFA) product line that was discontinued in Japan. Profit jumped to $14 million or $0.37 per share from the year ago profit of $2.9 million or $0.08 per share. On an adjusted basis, earnings spiked 31.5% to $0.25 per share.
Geographically, US net sales fell short of expectations, declining 2.8%, hurt by declining sales of Venous, PICCs, and RFA businesses. However, international sales experienced a positive growth due to consistent performance across all the business units.
Outlook
AngioDynamics reaffirmed its financial guidance for fiscal year 2018 and expects net sales in the range of $345 million to $350 million. Adjusted EPS is expected in the range of $0.64 to $0.68, excluding any impact from the 2017 Tax Reform Act. Including the impact of Tax Reform, adjusted EPS is eyed in the range of $0.70 to $0.74.
Most Popular
CVX Earnings: Chevron reports lower revenue and profit for Q1 2024
Energy exploration company Chevron Corporation (NYSE: CVX) announced first-quarter 2024 financial results, reporting a decline in net profit and revenues. Net income attributable to Chevron Corporation was $5.50 billion or
ABBV Earnings: AbbVie reports lower adj. profit for Q1 2024; revenue edges up
Specialty biopharmaceutical company AbbVie, Inc. (NYSE: ABBV) Friday announced first-quarter 2024 financial results, reporting a decline in adjusted earnings and a modest rise in revenues. The company reported worldwide net
CL Earnings: Key quarterly highlights from Colgate-Palmolive’s Q1 2024 financial results
Colgate-Palmolive Company (NYSE: CL) reported first quarter 2024 earnings results today. Net sales increased 6.2% year-over-year to $5.06 billion. Organic sales increased 9.8%. Net income attributable to Colgate-Palmolive Company was